


cardiovascular disorders including coronary artery disease, neuroinflammation, neurological disorders, pain and immunological disorders, asthma, allergic disorders, inflammation, systemic lupus erythematosus, ..

- 5 In another aspect, the invention provides a pharmaceutical composition for treating an ocular inflammatory disease, comprising a compound represented by Formula I:



Formula I

- 10 wherein:

R^1 is sec-butyl, C_{6-10} aryl, $-CH_2-$ (C_{6-10})aryl, $-CH_2-$ heterocycle, C_{4-8} cycloalkyl or C_{3-8} cycloalkenyl or heterocycle;

R^2 is halogen or methyl;

R^3 is halogen;


- 15 R^4 is H, methyl or halogen;


R^5 is OR^6 or NH_2 ; and

R^6 is H or C_{2-4} alkyl;

or a pharmaceutically acceptable salt thereof;

or a compound selected from the group consisting of:





10 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 FPR2 agonists show potent anti-inflammatory activity in endotoxin-induced uveitis model in rats.

Figure 2 FPR2 agonists show potent anti-inflammatory activity in endotoxin-induced uveitis model in rats.

15

Figure 3 shows accelerated healing and re-epithelialization in a rabbit model of corneal wound as exemplified by Compound 3, $\{[(2S,3S)-2-\{[(4-bromophenyl)carbamoyl]amino\}-3-methylpentanoyl]amino\}acetic\ acid$.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of
10 at least one agonist of FPR2.


In another aspect, the invention provides the use of at least one agonist of FPR2 for the manufacture of a medicament for the treatment of an ocular inflammatory disease or condition mediated by FPR2 in a mammal.

In another aspect, the invention provides a method for treating ocular
15 inflammatory diseases, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N.13/668,835, provided that the compounds have binding activity at the FPR2 receptor.

In another aspect, the invention provides the use of at least one compound as
20 disclosed in U.S. patent application S.N.13/668,835 for the manufacture of a medicament for the treatment of an ocular disease or condition mediated by

What is claimed is:

1. A pharmaceutical composition for treating an ocular inflammatory disease, comprising a compound represented by Formula I:



Formula I

wherein:

R^1 is sec-butyl, C_{6-10} aryl, $-CH_2-$ (C_{6-10})aryl, $-CH_2$ -heterocycle, C_{4-8} cycloalkyl or C_{3-8} cycloalkenyl or heterocycle;

R^2 is halogen or methyl;

R^3 is halogen;


R^4 is H, methyl or halogen;


R^5 is OR^6 or NH_2 ; and

R^6 is H or C_{2-4} alkyl;


or a pharmaceutically acceptable salt thereof;

or a compound selected from the group consisting of:





3. The pharmaceutical composition of claim 1, wherein the compound is:



4. The pharmaceutical composition of any one of claims 1 to 3, wherein the ocular inflammatory disease is selected from: uveitis, dry eye, keratitis, allergic eye disease, infectious keratitis, herpetic keratitis, corneal angiogenesis, lymphangiogenesis, retinitis, choroiditis, acute multifocal placoid pigment epitheliopathy, Behcet's disease, post-surgical corneal wound healing, wet and dry age-related macular degeneration (ARMD).